Dose Rounding Initiative at Cancer Specialists of North Florida
Kristie Fox, Pharm D | Clinical Oncology Pharmacist

**Background**
- Infusion therapy for oncology remains one of the highest expenditures in healthcare.
- Cost savings on infusion therapy is crucial to provide value-based care for patients and medically integrated practices, especially within the Oncology Care Model.
- HOPA’s position statement offers guidance on rounding of infusion doses to minimize these costs.

**Objectives**
- The objective of this initiative is to evaluate the impact of implementing dose rounding within a medically integrated oncology practice.
- Another objective of this initiative is to determine the cost savings advantage from instituting dose rounding on high-cost therapies.

**Methods**
- Collaboration between the clinical pharmacist and the reimbursement specialist to determine which patient therapies could be adjusted to the nearest vial size (within 10%) while ensuring patient safety.
- Used a stepwise approach to roll out the dose rounding initiative:
  - Phase 1: Alimta®, Opdivo®, Avastin® and biosimilars
  - Phase 2: Herceptin® and biosimilars, Perjeta®, Darzalex®, Sarclisa®
  - Phase 3: Erbitux®, Vectibix® and Treanda®
  - Phase 4: Rituxan® and biosimilars and all IVIG
  - Phase 5: Enhertu®, Trodelvy®, Polivy™, Empliciti®, Kyprolis®, Velcade®
  - Phase 6: Adcetris®, Yervoy®, Abraxane®, Gazyva®, Imfinzi®, Blenrep®, Jevtana®, Vidaza®

**Results**
- Between June 14, 2021, and September 24, 2021, 635 doses of the selected drugs were rounded down to the nearest vial size for cost savings. Using wholesale acquisition cost (WAC) pricing, the drug cost-savings was approximately $377,000. The drugs with the highest savings were rituximab-pwr (Ruxience®) and pemetrexed (Alimta®), with a savings of $76,890 and $62,575, respectively.

**Conclusion**
- There is a clear and significant cost savings seen at Cancer Specialists of North Florida with the implementation of the dose rounding initiative.
- Continued monitoring and identification of cost savings opportunities will be evaluated and tracked by the clinical pharmacist and team.
- Further data collection will be valuable to this rounding initiative and allow for publication of the research results.

### Dose Rounding Data

<table>
<thead>
<tr>
<th>Phase</th>
<th>Therapies Impacted (Brand name)</th>
<th>Number of Doses Rounded</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Alimta®, Opdivo®, Avastin®, Mvasi®, and Zirabev®</td>
<td>217</td>
</tr>
<tr>
<td>2</td>
<td>Herceptin®, Kanjinti®, Trazimera™, Darzalex®, Sarclisa®</td>
<td>141</td>
</tr>
<tr>
<td>3</td>
<td>Erbitux®, Vectibix®, and Treanda®</td>
<td>56</td>
</tr>
<tr>
<td>4</td>
<td>Rituxan® and Ruxience®</td>
<td>134</td>
</tr>
<tr>
<td>5</td>
<td>Empliciti® and Kyprolis®</td>
<td>40</td>
</tr>
<tr>
<td>6</td>
<td>Abraxane® and Imfinzi®</td>
<td>47</td>
</tr>
</tbody>
</table>

**References**